https://scholars.lib.ntu.edu.tw/handle/123456789/467852
標題: | Similar outcomes between vitamin K and non-vitamin K antagonist oral anticoagulants associated intracerebral hemorrhage | 作者: | Chen S.-J. SHIN-JOE YEH SUNG-CHUN TANG SHIN YI LIN LI-KAI TSAI JIANN-SHING JENG |
公開日期: | 2020 | 卷: | 119 | 期: | 1P1 | 起(迄)頁: | 106-112 | 摘要: | Background: The application of non-vitamin K antagonist oral anticoagulant (NOAC) reduces the risk of intracerebral hemorrhage (ICH) in comparison with vitamin K antagonist (VKA). However, the features and outcomes of NOAC-associated ICH are still unclear, especially for Asian populations. Methods: We retrospectively analyzed 49 consecutive patients who had spontaneous ICH while using NOAC or VKA. We compared the clinical characteristics, ICH volume, 7-day and 3-month mortality, and functional outcomes at discharge and 3 months post-stroke using the modified Rankin Scale (mRS) between NOAC- and VKA-associated ICH. The clinical features, ICH volume, ICH location, and/or treatment methods were statistically adjusted. Results: Among the 49 ICH patients, 15 (30.6%) were using NOAC and 34 (69.4%) were taking VKA. There were no significant differences in the initial ICH volume between groups (mean volume 34.2 ± 43.8 vs. 59.4 ± 46.5 mL, p = 0.061). The percentage of early mortality (within 7 days post-ICH) was significantly lower in the NOAC group (13.3% vs. 44.1%; p = 0.047), but the 3-month mortality was similar (33.3% vs. 47.1%; p = 0.294). The functional outcome was equally poor in both groups at discharge (p = 0.670) and 3 months post-ICH (mean mRS score 4.7 ± 1.3 vs. 4.6 ± 1.7, p = 0.766). Conclusion: There were no significant differences in initial ICH volume, 90-day mortality, or functional outcomes between NOAC and VKA-associated ICH in Asians. ? 2019 |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/467852 | ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.02.008 | SDG/關鍵字: | antivitamin K; apixaban; creatinine; dabigatran; fresh frozen plasma; idarucizumab; prothrombin complex; rivaroxaban; vitamin K group; anticoagulant agent; fibrinolytic agent; vitamin K group; adult; Article; Asian; atrial fibrillation; brain hemorrhage; CHA2DS2-VASc score; clinical article; clinical feature; coronary artery disease; creatinine clearance; deep vein thrombosis; female; follow up; human; international normalized ratio; liver cell carcinoma; liver transplantation; male; mortality; outcome assessment; Rankin scale; retrospective study; valvular heart disease; x-ray computed tomography; aged; brain hemorrhage; middle aged; mortality; oral drug administration; register; survival analysis; Taiwan; time factor; very elderly; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Registries; Retrospective Studies; Survival Analysis; Taiwan; Time Factors; Vitamin K |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。